Sumitomo Dainippon Pharma Co Ltd (DNPUF)
OTHER OTC:DNPUF
Holding DNPUF?
Track your performance easily

Sumitomo Dainippon Pharma Co (DNPUF) Stock Price & Analysis

7 Followers

DNPUF Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%1.05%2.64%96.31%
0.00%
Insiders
2.64% Other Institutional Investors
96.31% Public Companies and
Individual Investors

DNPUF FAQ

What was Sumitomo Dainippon Pharma Co Ltd’s price range in the past 12 months?
Sumitomo Dainippon Pharma Co Ltd lowest stock price was $1.73 and its highest was $5.10 in the past 12 months.
    What is Sumitomo Dainippon Pharma Co Ltd’s market cap?
    Currently, no data Available
    When is Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date?
    Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date is Oct 28, 2024 which is in 64 days.
      How were Sumitomo Dainippon Pharma Co Ltd’s earnings last quarter?
      Sumitomo Dainippon Pharma Co Ltd released its earnings results on Jul 31, 2024. The company reported $0.278 earnings per share for the quarter, beating the consensus estimate of -$0.073 by $0.351.
        Is Sumitomo Dainippon Pharma Co Ltd overvalued?
        According to Wall Street analysts Sumitomo Dainippon Pharma Co Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Sumitomo Dainippon Pharma Co Ltd pay dividends?
          Sumitomo Dainippon Pharma Co Ltd pays a Annually dividend of $0.05 which represents an annual dividend yield of N/A. See more information on Sumitomo Dainippon Pharma Co Ltd dividends here
            What is Sumitomo Dainippon Pharma Co Ltd’s EPS estimate?
            Sumitomo Dainippon Pharma Co Ltd’s EPS estimate is -$0.31.
              How many shares outstanding does Sumitomo Dainippon Pharma Co Ltd have?
              Sumitomo Dainippon Pharma Co Ltd has 397,900,150 shares outstanding.
                What happened to Sumitomo Dainippon Pharma Co Ltd’s price movement after its last earnings report?
                Sumitomo Dainippon Pharma Co Ltd reported an EPS of $0.278 in its last earnings report, beating expectations of -$0.073. Following the earnings report the stock price went up 4.38%.
                  Which hedge fund is a major shareholder of Sumitomo Dainippon Pharma Co Ltd?
                  Currently, no hedge funds are holding shares in DNPUF
                  ---

                  Sumitomo Dainippon Pharma Co Stock Smart Score

                  10
                  Unlock Smart Score
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Company Description

                  Sumitomo Dainippon Pharma Co Ltd

                  Sumitomo Dainippon Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
                  ---

                  DNPUF Stock 12 Month Forecast

                  Average Price Target

                  $3.07
                  ▼(-31.78% Downside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","1.75":"$1.75","2.5":"$2.5","3.25":"$3.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.4633,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.562842,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,1.75,2.5,3.25,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2023","6":"Mar<br/>2024","9":"May<br/>2024","12":"Aug<br/>2024","25":"Aug<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.94,2.980253846153846,3.0205076923076923,3.0607615384615383,3.1010153846153847,3.1412692307692307,3.1815230769230767,3.221776923076923,3.262030769230769,3.3022846153846155,3.3425384615384615,3.3827923076923074,3.423046153846154,{"y":3.4633,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.94,2.9499999999999997,2.96,2.9699999999999998,2.98,2.9899999999999998,3,3.01,3.02,3.03,3.04,3.05,3.06,{"y":3.07,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.94,2.910987846153846,2.8819756923076922,2.8529635384615384,2.8239513846153845,2.7949392307692307,2.765927076923077,2.736914923076923,2.707902769230769,2.6788906153846153,2.6498784615384614,2.6208663076923076,2.5918541538461537,{"y":2.562842,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.56,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.46,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.88,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.2,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.26,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.42,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.4,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.68,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.54,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.16,"date":1715904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1717718400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1720137600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1722556800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Moderna
                  AstraZeneca
                  Takeda Pharmaceutical Company
                  Bristol-Myers Squibb

                  Best Analysts Covering DNPUF

                  1 Year
                  Kasumi HarutaUBS
                  Not Ranked
                  1 Year Success Rate
                  0/0 ratings generated profit
                  0%
                  1 Year Average Return
                  0.00%
                  downgraded a sell rating last month
                  Copying Kasumi Haruta's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis